Proposed PIL NL/H/0653/001/IB/024/G. MONOFREE DEXAMETHASON 1 mg/ml, eye drops, solution in single-dose container Dexamethasone phosphate

Similar documents
Package leaflet: Information for the patient. IKERVIS 1 mg/ml, eye drops, emulsion ciclosporin

Package Leaflet - Information for the User. TOBRADEX 3 mg/ml/1 mg/ml Eye Drops, Suspension Tobramycin and Dexamethasone

Package leaflet: Information for the patient. Verkazia 1 mg/ml eye drops emulsion ciclosporin

D90 (27/10/2005) Final SmPC NL/H/653/01

PRED FORTE 1% w/v Eye Drops, Suspension Prednisolone acetate

Package leaflet: Information for the user. PRED MILD STERILE OPHTHALMIC SUSPENSION 0.12% w/v Eye Drops, Suspension Prednisolone Acetate

Package Leaflet: Information for the user. LUMIGAN 0.3 mg/ml, eye drops, solution, in single-dose container Bimatoprost

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

PACKAGE LEAFLET: INFORMATION FOR THE USER ACULAR 0.5% w/v EYE DROPS, SOLUTION (Ketorolac trometamol)

Package leaflet: Information for the user. Latanoprost Pfizer 50 micrograms/ml Eye drops, solution Latanoprost

Package leaflet: Information for the user. <product name> 3 mg/ml eye drops, solution. Ofloxacin

Package leaflet: Information for the user. Xalatan 50 micrograms/ml Eye drops, solution Latanoprost

Package leaflet: Information for the user. NEVANAC 1 mg/ml eye drops, suspension Nepafenac

Package leaflet: Information for the user Oftaquix 5 mg/ml eye drops, solution. Levofloxacin

Package leaflet: Information for the patient. Brimonidine Biogaran 2 mg/ml eye drops, solution. brimonidine tartrate

Package leaflet: Information for the patient. Dexametason Abcur 4 mg tablets. Dexamethasone

Package leaflet: Information for the user. Catacrom 2 % w/v Eye Drops, Solution. Sodium cromoglicate

Dorzolamide 20 mg/ml Eye Drops, Solution

Package Leaflet: Information for the user. NEVANAC 3 mg/ml eye drops, suspension nepafenac

PACKAGE LEAFLET: INFORMATION FOR THE USER ToboDexin 3 mg/g+1 mg/g eye ointment Tobramycin + Dexamethasone

Package leaflet: Information for the user. Relestat, 0.5 mg/ml, eye drops, solution Epinastine hydrochloride

Package leaflet: Information for the user. Carmellose sodium

PATIENT INFORMATION LEAFLET

Package leaflet: information for the user. OZURDEX 700 micrograms intravitreal implant in applicator dexamethasone

Package leaflet: Information for the user

Package leaflet: Information for the user. GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution, in single-dose container Bimatoprost/timolol

Package leaflet: Information for the user. <PRODUCT NAME> 10 g powder for oral solution in sachet Macrogol 4000

Package leaflet: Information for the patient. Latanoprost 50 micrograms/ml eye drops, solution latanoprost

MAXIDEX TM Eye Ointment 0.1%

MAXIDEX Eye Drops 0.1%

Package leaflet: Information for the patient. Xemacort 20 mg/g + 1 mg/g cream (fusidic acid and betamethasone)

Pilocarpine 2% w/v Eye Drops, solution. Pilocarpine 4% w/v Eye Drops, solution. Pilocarpine Hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER Nicorandil 10 mg Tablets Nicorandil 20 mg Tablets nicorandil

PACKAGE LEAFLET: INFORMATION FOR THE USER. Otrivin Menthol (without preservative) 1 mg/ml nasal spray, solution Xylometazoline hydrochloride

TAFEN NASAL 50mcg nasal spray, suspension

Package leaflet: Information for the user Pulmicort Respules 0.5 mg, Nebuliser Suspension budesonide

PATIENT INFORMATION LEAFLET

MAXITROL Eye Ointment

ALPHAGAN EYE DROPS BRIMONIDINE TARTRATE

Package leaflet: Information for the user

Package leaflet: Information for the user. Fluticrem 0.05% cream Fluticasone propionate

ILUVIEN 190 micrograms intravitreal implant in applicator (fluocinolone acetonide)

Package leaflet: Information for the user. GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution Bimatoprost/timolol

PATIENT INFORMATION LEAFLET. PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM LUMIGAN 0,01 %, bimatoprost 0,1 mg/ml eye drops

Package leaflet: Information for the patient. xylometazoline hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER Rhinocort Aqua, 64 micrograms, Nasal Spray Budesonide

Package leaflet: Information for the user. Bricanyl Respules 2.5 mg/ml Nebuliser Solution terbutaline sulfate

Package leaflet: Information for the user. Ebateva 20 mg Orodispersible Tablets. Ebastine

Package leaflet: Information for the user. Zidoval 7.5 mg/g Vaginal Gel Metronidazole

1. What Miacalcic is and what it is used for

AUSTRALIAN PRODUCT INFORMATION FLAREX (FLUOROMETHOLONE ACETATE) EYE DROPS SUSPENSION

Package leaflet: Information for the user. Nocdurna 25 microgram oral lyophilisate Nocdurna 50 microgram oral lyophilisate.

NEW ZEALAND DATA SHEET 1. PRODUCT NAME

Package leaflet: Information for the user. Monovo 1 mg/g cutaneous emulsion. mometasone furoate

TIMALEN 0.5% eye drops

Package Leaflet: Information for the user

Package leaflet: Information for the user. Tuberculin PPD RT23 "SSI" 2 T.U./0.1 ml, solution for injection Tuberculin PPD RT 23

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Beclometasone dipropionate

Unofficial translation of the German package leaflet. Package leaflet: Information for the user

Package leaflet: Information for the patient. Mometasone furoate 0.1%w/w Ointment (mometasone furoate)

Package Leaflet: INFORMATION FOR THE USER. PARACODIN 10 mg/g oral drops, solution (dihydrocodeine hydrorhodanide)

MAXITROL* Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment, USP 3.5 mg (as neomycin sulfate), 6000 IU/g, 0.

1.3.1 PACKAGE LEAFLET: INFORMATION FOR THE USER

HIDROKORTIZON SA HLORAMFENIKOLOM (10 mg + 2 mg) / ml, eye drops, suspension

PATIENT INFORMATION LEAFLET. Nasoxyl nasal spray solution 1 mg/ml

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Estracyt Capsules Estramustine phosphate 140mg (as estramustine sodium phosphate)

Proctosedyl Ointment Hydrocortisone/Cinchocaine hydrochloride/framycetin sulphate/aesculin

PACKAGE LEAFLET: INFORMATION FOR THE USER. Budesonide Teva 0.5 mg/2 ml Nebuliser Suspension Budesonide

1 What Zofran Suppositories are and what they are used for

Package leaflet: Information for the patient BETAXOLOL 0.5% EYE DROPS. Betaxolol (as hydrochloride)

Package leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets

Package leaflet: Information for the user

2 What you need to know before you use Beconase. Package Leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Turbohaler budesonide. 1. What Pulmicort Turbohaler is and what it is used for

Ventolin Accuhaler 200 micrograms salbutamol sulfate

Package leaflet: Information for the user. Omnilax 10 g powder for oral solution, sachet. Macrogol 4000

Package leaflet: Information for the User Clarityn 1 mg/ml syrup Loratadine

Package leaflet: Information for the patient

Do not use Allergo-COMOD eye drops - if you are hypersensitive against sodium cromoglicate (Ph. Eur.) or one of the other ingredients.

Package leaflet: Information for the user. Nasacort 55 micrograms/dose, nasal spray suspension Triamcinolone acetonide

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride

PACKAGE LEAFLET Package leaflet: Information for the user. Ranitidin Actavis 150 mg and 300 mg film-coated tablets. Ranitidine

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER

Patient Leaflet : Information for the user Locoid Cream 0.1% w/w Hydrocortisone butyrate

Package leaflet: Information for the user

FASTUM 2.5% gel PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1. WHAT FASTUM GEL IS AND WHAT IT IS USED FOR

Package leaflet: Information for the patient. Plenadren 5 mg modified-release tablets Plenadren 20 mg modified-release tablets Hydrocortisone

PACKAGE LEAFLET: INFORMATION FOR THE USER

Fultium can also be used as an adjunct to specific bone loss medication

PACKAGE LEAFLET: INFORMATION FOR THE USER. Lidokain Isdin 40 mg/g cream. Lidocaine

1. What Octostim Nasal Spray is and what it is used for

PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Respules 1 mg/2 ml Nebuliser Suspension budesonide

Package leaflet: Information for the user. Colecalciferol 3000 IU/ml Oral Solution (colecalciferol)

PACKAGE LEAFLET: INFORMATION FOR THE USER. GRAZAX 75,000 SQ-T oral lyophilisate

Package leaflet: Information for the patient UNITED KINGDOM Feldene 5mg/g Gel piroxicam

Tiorfan Hidrasec Tiorfix Tiorfast 100 mg PACKAGE LEAFLET

Package leaflet: Information for the user. Optilamid 10 mg/ml, oogdruppels, suspensie Brinzolamide

Cutivate 0.05% w/w Cream fluticasone propionate

Transcription:

Proposed PIL NL/H/0653/001/IB/024/G PACKAGE LEAFLET: INFORMATION FOR THE USER MONOFREE DEXAMETHASON 1 mg/ml, eye drops, solution in single-dose container Dexamethasone phosphate Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What MONOFREE DEXAMETHASON is and what it is used for 2. What you need to know before you use MONOFREE DEXAMETHASON 3. How to use MONOFREE DEXAMETHASON 4. Possible side effects 5. How to store MONOFREE DEXAMETHASON 6. Contents of the pack and other information 1. WHAT MONOFREE DEXAMETHASON IS AND WHAT IT IS USED FOR MONOFREE DEXAMETHASON is an eye drop in single-dose container, which contains a substance called dexamethasone. This substance is a corticosteroid which inhibits inflammatory symptoms. MONOFREE DEXAMETHASON is indicated for treatment of the inflammation of your eye(s). The eye should not be infected (red eye, secretions, tearing,...); otherwise a specific treatment of your infection should be combined (see section 2) 2. WHAT YOU NEED TO KNOW BEFORE YOU USE MONOFREE DEXAMETHASON DO NOT use MONOFREE DEXAMETHASON If you are suffering from an ocular infection which could be bacterial (acute purulent infection), fungal, viral (herpetic virus, vaccine virus, varicella zona virus) or amoebic, If you have corneal damages (perforation, ulcerations or lesions associated with incomplete healing), If you have ocular hypertension known to be caused by glucosteroids (family of corticosteroids), If you are allergic (hypersensitive) to dexamethasone sodium phosphate, or any of the other ingredients of MONOFREE DEXAMETHASON. Warnings and precautions

Talk to your doctor or pharmacist before using MONOFREE DEXAMETHASON DO NOT INJECT, DO NOT SWALLOW Avoid contact between the dispenser tip and the eye or eyelids. Close ophthalmic monitoring is required during the use of MONOFREE DEXAMETHASON in any case and in particular: - for children and the elderly. More frequent ophthalmic monitoring is recommended, - if you have an ocular infection. Only use MONOFREE DEXAMETHASON if the infection is being treated with an anti-infective treatment, - if you are suffering from a corneal ulcer. Do not use a local dexamethasone treatment or MONOFREE DEXAMETHASON, unless inflammation is the main cause of delayed healing, - if you suffer from increased intraocular pressure. If you have already experienced adverse reactions to local steroids treatment, resulting in increased ocular pressure, you are at risk of developing increased ocular pressure if treated by MONOFREE DEXAMETHASON, - if you have glaucoma. Children: you should avoid continual, long-term treatment. Severe allergic conjunctivitis: if you have severe allergic conjunctivitis that fails to respond to standard treatment, only use MONOFREE DEXAMETHASON over a short period of time. Diabetic: if you are diabetic, inform your ophthalmologist. Red eye: if you have a red eye that has not been diagnosed, do not use MONOFREE DEXAMETHASON. Contact lenses: you should avoid wearing contact lenses during treatment with MONOFREE DEXAMETHASON. Talk to your doctor if you experience swelling and weight gain around the trunk and in the face as these are usually the first manifestations of a syndrome called Cushing s syndrome. Suppression of the adrenal gland function may develop after stopping a long-term or intensive treatment with MONOFREE DEXAMETHASON. Talk to your doctor before stopping the treatment by yourself. These risks are especially important in children and patients treated with a drug called ritonavir or cobicistat. Contact your doctor if you experience blurred vision or other visual disturbances. Other medicines and MONOFREE DEXAMETHASON If you are using any other medicine to be applied in the eye, you should wait 15 minutes between each application. Tell your doctor if you are using ritonavir or cobicistat, as this may increase the amount of dexamethasone in the blood. Precipitation of calcium phosphate on the surface of the cornea has been observed during the local concomitant use of steroids and beta-blockers. Tell your doctor or pharmacist if you are using or have recently used or might use any other medicines. Pregnancy and breast-feeding There is not sufficient information on the use of MONOFREE DEXAMETHASON during pregnancy to evaluate the potential side effects. Therefore the use of MONOFREE DEXAMETHASON during pregnancy is not recommended.

It is not known whether this medicine is excreted in breast milk. However the total dose of dexamethasone is low. Therefore MONOFREE DEXAMETHASON can be used during breast-feeding. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines As with all eye drops, temporary blurred vision, or other sight defects may affect the ability to drive or use machines. Do not drive or use machines until normal vision has returned. MONOFREE DEXAMETHASON contains phosphates This medicine contains 80 micrograms phosphates in each drop. 3. HOW TO USE MONOFREE DEXAMETHASON Dose Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is 1 drop, 4 to 6 times daily in the affected eye. In serious case, treatment can start with 1 drop every hour and be reduced to 1 drop every 4 hours, once a favourable response has been observed. Gradual dose reduction is recommended in order to avoid relapse. - In elderly people: there is no need to adjust the dose. - In children: the continual, long-term treatment should be avoided. Method of administration Ocular use: this medicine is intended to be administered into the eye. Wash your hands thoroughly before using the product. Introduce one drop into the affected eye, while looking upwards and pulling the lower eyelid down with your finger. Immediately after application, apply light pressure with your finger on the internal corner of the treated eye for few minutes (in order to reduce the risk of systemic reactions and to increase penetration of the active substance into the eye). Discard the single-dose container after use. Do not keep it for subsequent use. Frequency of administration 4 to 6 times daily. Duration of treatment The duration treatment usually varies from a few days to a maximum of 14 days. If you use more MONOFREE DEXAMETHASON than you should Rinse the eye with sterile water if you have applied too much product to your eye and there is prolonged irritation. Immediately contact your doctor or your pharmacist. If you forget to use MONOFREE DEXAMETHASON Do not use a double dose to make up for a forgotten dose.

If you stop using MONOFREE DEXAMETHASON Do not stop using the treatment abruptly. Always consult your doctor if you are considering stopping the treatment. If you have any further questions on the use of this product, ask your doctor or pharmacist. 4. POSSIBLE SIDE EFFECTS Like all medicines, this medecine can cause side effects, although not everybody gets them: Endocrine disorders: Not known: frequency cannot be estimated from the available data Hormone problems: growth of extra body hair (particularly in women), muscle weakness and wasting, purple stretch marks on body skin, increased blood pressure, irregular or missing periods, changes in the levels of protein and calcium in your body, stunted growth in children and teenagers and swelling and weight gain of the body and face (called Cushing s syndrome') (see section 2, Warnings and precautions ). Eye disorders: Very common: may affect more than 1 in 10 people high intraocular pressure, after 2 weeks of treatment. Common: may affect up to 1 in 10 people discomfort, irritation, burning, stinging, itching and blurred vision after application. These are usually short-term and mild symptoms. Uncommon: may affect up to 1 in 100 people allergic and hypersensitivity reactions to one of the ingredients in the eye drops, delayed healing, opacification of the crystalline lens (cataract), infections, glaucoma. Very rare: may affect up to 1 in 10,000 people inflammation of eye membranes (conjunctivitis), dilation of the pupil (mydriasis), facial swelling (facial oedema), drooping eyelids (ptosis), inflammation of the iris (uveitis), calcification of the cornea, inflammation of the cornea (crystalline keratopathy), variations in the thickness of the cornea, corneal oedema, ulcerations of the cornea, perforation of the cornea.

If you suffer from severe damage to the clear layer at the front of the eye (the cornea), phosphates may cause in very rare cases cloudy patches on the cornea due to calcium build-up during treatment. Reporting of side effects If you get any side effects talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. 5. HOW TO STORE MONOFREE DEXAMETHASON Keep this medicine out of the sight and reach of children. Do not use MONOFREE DEXAMETHASON after the expiry date which is stated on the single-dose container after EXP. The expiry date refers to the last day of that month. After first opening of the sachet: use the single-dose containers within 15 days. After opening of the single-dose container: use immediately and discard the singledose container after use. Keep the single-dose containers in the sachet, in order to protect from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect environment. 6. CONTENTS OF THE PACK AND OTHER INFORMATION What MONOFREE DEXAMETHASON contains - The active substance is dexamethasone sodium phosphate. Each millilitre of solution contains 1 mg of dexamethasone phosphate (as dexamethasone sodium phosphate). - The other ingredients are disodium edetate, disodium phosphate dodecahydrate, sodium chloride and water for injections. What MONOFREE DEXAMETHASON looks like and contents of the pack MONOFREE DEXAMETHASON is a clear colourless to slightly brown eye drops solution supplied in single-dose container. Each single-dose container contains 0.4 ml of solution. The pack contains 10, 20, 30, 50 or 100 single-dose containers packed in sachets. Marketing Authorisation Holder [To be completed nationally] Manufacturer EXCELVISION Rue de la Lombardière

07100 ANNONAY FRANCE Or Laboratoire UNITHER ZI de la Guérie 50211 COUTANCES CEDEX FRANCE This medicinal product is authorised in the Member States of the EEA under the following names: [To be completed nationally] This leaflet was last revised in {MM/YYYY}. Detailed information on this medicine is available on the web site of {MA/Agency}.